doi: 10.1038/s41598-021-87387-5.
- PMID: 33854102
- DOI: 10.1038/s41598-021-87387-5
Abstract
Regulators of G protein signaling (RGS) accelerate the GTPase activity of G proteins to enable rapid termination of the signals triggered by G protein-coupled receptors (GPCRs). Activation of several GPCRs, including cannabinoid receptor 2 (CB2R) and adenosine A1 receptor (A1AR), protects against noise and drug-induced ototoxicity. One such drug, cisplatin, an anticancer agent used to treat various solid tumors, produces permanent hearing loss in experimental animals and in a high percentage of cancer patients who undergo treatments. In this study we show that cisplatin induces the expression of the RGS17 gene and increases the levels of RGS17 protein which contributes to a significant proportion of the hearing loss. Knockdown of RGS17 suppressed cisplatin-induced hearing loss in male Wistar rats, while overexpression of RGS17 alone produced hearing loss in vivo. Furthermore, RGS17 and CB2R negatively regulate the expression of each other. These data suggest that RGS17 mediates cisplatin ototoxicity by uncoupling cytoprotective GPCRs from their normal G protein interactions, thereby mitigating the otoprotective contributions of endogenous ligands of these receptors. Thus, RGS17 represents a novel mediator of cisplatin ototoxicity and a potential therapeutic target for treating hearing loss.
Similar articles
-
Adenosine A1 Receptor Protects Against Cisplatin Ototoxicity by Suppressing the NOX3/STAT1 Inflammatory Pathway in the Cochlea.J Neurosci. 2016 Apr 6;36(14):3962-77. doi: 10.1523/JNEUROSCI.3111-15.2016.PMID: 27053204 Free PMC article.
-
Regulators of G-Protein signaling RGS10 and RGS17 regulate chemoresistance in ovarian cancer cells.Mol Cancer. 2010 Nov 2;9:289. doi: 10.1186/1476-4598-9-289.PMID: 21044322 Free PMC article.
-
Mechanisms of Cisplatin-Induced Ototoxicity and Otoprotection.Front Cell Neurosci. 2017 Oct 27;11:338. doi: 10.3389/fncel.2017.00338. eCollection 2017.PMID: 29163050 Free PMC article. Review.
-
Regulator of G Protein Signaling 17 as a Negative Modulator of GPCR Signaling in Multiple Human Cancers.AAPS J. 2016 May;18(3):550-9. doi: 10.1208/s12248-016-9894-1. Epub 2016 Feb 29.PMID: 26928451 Free PMC article. Review.
-
The Endocannabinoid/Cannabinoid Receptor 2 System Protects Against Cisplatin-Induced Hearing Loss.Front Cell Neurosci. 2018 Aug 21;12:271. doi: 10.3389/fncel.2018.00271. eCollection 2018.PMID: 30186120 Free PMC article.
References
-
- Arnesano, F. & Natile, G. Mechanistic insight into the cellular uptake and processing of cisplatin 30 years after its approval by FDA. Coord. Chem. Rev. 253, 2070–2081. https://doi.org/10.1016/j.ccr.2009.01.028 (2009). – DOI
-
- Higby, D. J., Wallace, H. J. Jr., Albert, D. J. & Holland, J. F. Diaminodichloroplatinum: A phase I study showing responses in testicular and other tumors. Cancer 33, 1219–1225. https://doi.org/10.1002/1097-0142(197405)33:5%3c1219::aid-cncr2820330505… (1974). – DOI – PubMed
-
- Fuertes, M. A., Alonso, C. & Pérez, J. M. Biochemical modulation of cisplatin mechanisms of action: Enhancement of antitumor activity and circumvention of drug resistance. Chem. Rev. 103, 645–662. https://doi.org/10.1021/cr020010d (2003). – DOI – PubMed
-
- Florea, A. M. & Busselberg, D. Cisplatin as an anti-tumor drug: Cellular mechanisms of activity, drug resistance and induced side effects. Cancers 3, 1351–1371. https://doi.org/10.3390/cancers3011351 (2011). – DOI – PubMed – PMC
-
- Wang, D. & Lippard, S. J. Cellular processing of platinum anticancer drugs. Nat. Rev. Drug Discov. 4, 307–320. https://doi.org/10.1038/nrd1691 (2005). – DOI – PubMed
